Circulating antibodies against p53 protein in patients with ovarian carcinoma: Correlation with clinicopathologic features and survival

Cancer

Volumn 78, Issue 10, 1996, Pages 2146-2152

  Angelopoulou, Katerina ^a,b   Rosen, Barry ^c   Stratis, Michael ^d   Yu, He ^a,b   Solomou, Maria ^a   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

cancer monitoring; ovarian carcinoma; p53 autoantibodies; p53 protein; tumor markers; tumor suppressor genes

Indexed keywords

PROTEIN P53; TUMOR MARKER;

ANIMAL CELL; ANTIBODY DETECTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SURVIVAL; GENE MUTATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CARCINOMA; FEMALE; FLUOROIMMUNOASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029913527     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961115)78:10<2146::AID-CNCR15>3.0.CO;2-Z     Document Type: Article

References (23)

1. Caron de Fromentel C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosom Cancer 1992;4:1-15.
2. Hassapoglidou S, Diamandis EP, Sutherland DJA. Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogens 1993;8:1501-9.
3. Crawford LV, Piw DC, Ulbtook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-8.
4. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53 HSP70 complexes in breast cancer. Proc Natl Acad Sci USA 1992;89:3439-42.
5. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992;52:6380-4.
6. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, et al. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 1994;69:1115-9.
7. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the p53 mutation. Cancer Res 1992;52:4168-74.
8. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994;69:809-16.
9. Angelopoulou K, Diamandis EP. Quantification of antibodies against the p53 tumor suppressor gene product in the serum of cancer patients. Cancer 1993;6:315-21.
10. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480-7.
11. Houbiers JGA, Van der Burg SH, Van de Watering LMG, Tollenaar RAEM, Brand A, Van de Velde CJH, et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 1995; 72:637-41.
12. Green JA, Robertson BA, Campbell IR, Jenkins J. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. Cancer Detect Prev 1995;19:151-5.
13. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 1993;53:5872-6.
14. Peyrat JP, Jacques B, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995;345:621-2.
15. Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329:1550-9.
16. Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991;51:5171-6.
17. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al. Overexpression and mutation of p53 in epithelial ovarian cancer, Cancer Res 1991:51:2979-84.
18. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995:75:1327-38.
19. Murakami Y, Hayashi K, Sekiya T. Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res 1991;51:3356-61.
20. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunohistochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151:237-44.
21. Hassapoglidou S, Diamandis EP. Antibodies to p53 tumor suppressor gene product quantified in cancer patient serum with a time-resolved immunofluorometric technique. Clin Biochem 1992:25:445-9.
22. Christopoulos TK, Diamandis EP. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 1992;64:342-6.
23. Papanastasiou-Diamandi A, Christopoulos TK, Diamandis EP. Ultrasensitive thyrotropin immunoassay based on enzymatically amplified time-resolved fluorescence with a terbium chelate. Clin Chem 1992;38:545-8.